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Abstract
Nowadays, biomarkers are useful in the early detection and risk stratification of metabolic 
syndrome (MetS) patients. Studies confirmed the implication of adipokines, neuropep-
tides, inflammatory cytokines, prothrombotic factors, and others in MetS pathogenesis. 
Leptin:adiponectin ratio is useful in predicting insulin resistance and MetS severity; 
leptin is correlated with obesity and waist size and adiponectin is inversely related with 
MetS components. Ghrelin is inversely correlated with MetS components, and studies 
confirmed its role in MetS prediction. Regarding the pro-inflammatory cytokines, studies 
confirmed that interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha are positively 
correlated with hypertriglyceridemia, hypertension, fasting glucose levels, insulin 
resistance, and in postmenopausal women with central obesity. Oxidized low-density 
lipoprotein (LDL) levels could be implicated in insulin resistance. Recent studies also 
confirmed that novel biomarkers such as pentraxin-3 are positively correlated with MetS 
severity and the presence of vascular lesions, and it could bring new data on the MetS 
mechanism. Within this chapter, we review data on the contribution of biomarkers as 
well as on the stratification of MetS patients, discussing their key contribution for creat-
ing a risk assessment algorithm.
Keywords: metabolic syndrome, biomarkers, cytokines, obesity, insulin resistance, 
leptin, adiponectin, ghrelin, pentraxin-3, paraoxonase, interleukins
1. Introduction
Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors with a reported preva-
lence of 20–25% in general population [1] and also with an increased two-fold risk to develop 
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cardiovascular disease [2]. Recent studies have shown that, being involved in MetS pathogen-
esis, some adipokines, neuropeptides, inflammatory cytokines, prothrombotic factors, and 
others could be used in diagnosing and monitoring these patients.
Various studies confirmed that the leptin:adiponectin ratio (LAR) could have a superior 
predictive power in determining insulin resistance and MetS severity than the use of leptin 
or adiponectin alone [3]. Leptin is positively correlated with obesity and waist size [4–8]. 
Adiponectin has important physiological functions in maintaining metabolic balance and is 
inversely related with MetS components independently of body mass index (BMI) [7, 9].
Ghrelin is inversely correlated with MetS components, and studies confirmed its role in MetS 
prediction. Also, a positive correlation of ghrelin levels with hypertension, insulin resistance, 
and obesity has been found [10–16].
Regarding the pro-inflammatory cytokines, studies confirmed that interleukin-6 (IL-6) and 
tumor necrosis factor alpha (TNF-α) are positively correlated with hypertriglyceridemia, 
hypertension, fasting glucose levels, insulin resistance, and in postmenopausal women with 
central obesity [17, 18, 19–25]. Oxidized low-density lipoprotein (LDL) levels have been found 
to be correlated with insulin resistance, hyperinsulinemia, impaired glycemic control, and 
excessive adipose tissue and could predict the occurrence of MetS [26–28].
Recent studies also confirmed that novel biomarkers such as pentraxin-3 are positively cor-
related with MetS severity and the presence of vascular lesions, and it could bring new data 
on the MetS mechanism. Also, pentraxin-3 (PTX3) was found to be correlated with low high-
density lipoprotein (HDL) cholesterol levels and high triglycerides [29–31].
Paraoxonase-1 (PON-1) was inversely correlated with the presence of MetS, more precisely 
with central obesity, hypertriglyceridemia, and hypertension [32–35]. Interleukin-10 (IL-10) 
is an anti-inflammatory cytokine, and decreased levels of IL-10 are associated with insulin 
resistance and the presence of MetS [36–39].
2. Leptin, adiponectin, and leptin:adiponectin ratio
2.1. Leptin
Leptin is a hormone produced mainly by white adipose tissue, but also by non-adipose ones 
(placenta, stomach, mammary gland, and immune system) [40, 41]. Its regulation is achieved 
through various factors dependable on the metabolic status (Figure 1). Thus, the implica-
tions of leptin in pathogenic mechanisms comprise energy homeostasis, obesity syndromes, 
metabolic dysfunctionalities, neuroendocrine function, and bone metabolism. The pathogenic 
pathways of leptin follow similar targets through different mechanisms [40]. Leptin binds 
to its functional receptor and activates several transduction pathways, such as Janus kinase 
(JAK)/signal transducers and activators of transcription (determines autophosphorylation 
of JAK1 and JAK2 with STAT3 activation), mitogen-activated protein kinase (activates this 
MAPK pathway in central and peripheral tissues), phosphatidylinositol-4,5-bisphosphate 
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3-kinase/protein kinase B (leptin activates directly PI3K in peripheral tissue), and AMP-
activated protein kinase [42, 43].
Since its discovery, many studies have focused on the role of leptin in the evaluation of car-
diovascular risk. High levels of leptin lead to a global and/or selective leptin resistance. MetS 
is a condition that favors leptin resistance through systemic inflammation, insulin resistance, 
hyperlipidemia, hypertension, atherosclerosis, and obesity [44]. Leptin levels correlate mainly 
with obesity and waist circumference, as it has been confirmed in numerous studies, the 
aspects of which are detailed in Table 1 [4–8].
2.2. Adiponectin
Adiponectin is a protein hormone produced exclusively by adipocytes. Its high-molecular 
weight form is proved to have the most intense metabolic activity. Circulating levels of adi-
ponectin are higher in females than in males due to the stimulating activity of testosterone on 
adiponectin secretion [45]. It plays an important role in metabolic balance, and its lower levels 
are correlated with an increased cardiac, vascular, and metabolic risk.
Figure 1. Factors that regulate leptin plasmatic levels.
Study Year Subjects Leptin and MetS
García-Jiménez 
et al.
2014 204 Leptin is strongly correlated with BMI; plasma leptin concentration is 
proportional to the degree of central obesity causing leptin resistance
Yoshinaga et al. 2008 321 Leptin was the most sensitive marker for predicting MetS in elementary 
school children
Lee et al. 2012 153 Elevated leptin in MetS women in postmenopausal
Gannage-Yared 
et al.
2006 153 Leptin was strongly correlated with waist size in Lebanese population
Yun et al. 2010 9995 Serum leptin levels increased as the components of MetS, thus reduction of 
leptin levels may be protective
Table 1. Leptin correlations with metabolic syndrome.
Biomarkers in Metabolic Syndrome
http://dx.doi.org/10.5772/intechopen.79427
91
In normal subjects, adiponectin has important physiological functions in maintaining the met-
abolic balance (Figure 2); therefore, in patients with MetS, adiponectin levels are decreased 
[43]. Numerous studies have demonstrated its positive effect on metabolic protection, mainly 
based on its potentially inhibitory activity on the atherogenic process [46]. Recent studies 
have shown that adiponectin is inversely correlated with MetS components and that it has 
benefic effects on metabolic disorders [47]. Hypoadiponectinemia induced by visceral obesity 
determines vascular changes and insulin resistance. Likewise, two clinical studies conducted 
by Gannage-Yared et al. and by Santaneimi et al. have demonstrated the correlation of adipo-
nectin with MetS independent of BMI [7, 9].
2.3. Leptin:adiponectin ratio
Various studies recommend using the leptin:adiponectin ratio (LAR) due to its increased pre-
dictive power, despite determining leptin and/or adiponectin alone. Recent data suggest the 
fact that leptin and adiponectin are two molecules that possess antagonistic effects. In addition, 
the study by Thorand et al. has been suggested that leptin and adiponectin interact with each 
other in order to modulate the risk of diabetes [3]. Therefore, Finucane et al. have demonstrated 
that LAR is a useful marker of insulin resistance in non-diabetic adults [48]. Lopez-Jaramillo 
et al. have emphasized the use of LAR in the evaluation of insulin resistance, and Kotani et al. 
have confirmed the predictive value of LAR in Japanese patients with MetS; other studies have 
also shown the correlation between LAR with all five MetS components [49–51].
3. Ghrelin
3.1. Generalities
Ghrelin is a peptide hormone produced in the gastrointestinal tract, and it has an important role 
in regulating the use of energy in human organism. Ghrelin undergoes posttranslational changes 
resulting in two circulating forms: unacylated ghrelin (UAG) and acylated ghrelin (AG) [51]. 
Figure 2. Metabolic balance mediated by adiponectin.
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This hormone acts directly on hypothalamus and indirectly by increasing the expression of 
orexigenic peptides such as neuropeptide Y, Agouti-related protein, proopiomelanocortin, 
and corticotropin-releasing hormone [52].
In addition to its effect on hunger, ghrelin has important effects on glucose homeostasis, 
energy homeostasis, heart, muscular atrophy, bone metabolism, and tumors [53]. Recent 
studies emphasize that AG excess is correlated with insulin resistance and metabolic altera-
tions; thereby, the AG/UAG ratio could play a role in the development of MetS [54].
3.2. Ghrelin and metabolic syndrome
Ghrelin is inversely associated with MetS components, and progressively lower ghrelin lev-
els are being correlated with its severity. Ukkola O et al. emphasized the correlation of low 
ghrelin levels in obese patients with metabolic syndrome [55]. Also, the positive correlation 
of ghrelin levels with hypertension, insulin resistance, and obesity has been confirmed by 
numerous studies. McLaughlin et al. have concluded that ghrelin correlates with MetS mainly 
based on obesity as well as they identified lower ghrelin levels in patients with MetS and 
obesity than in non-obese MetS patients [10]. Likewise, many studies confirm the relation 
between MetS and ghrelin [11–16].
4. Interleukin-6
4.1. Interleukin-6 and inflammation response
IL-6 is a human cytokine that plays important roles in acute and chronic inflammation, 
immune cell development, and the pathogenesis of autoimmune disease. It is known that 
the increased activity of IL-6 gene is associated with an elevated risk of developing diabetes 
mellitus [56]. Likewise, IL-6 is linked with all the components of the inner immunity and 
yields a pro-inflammatory effects explained by different pathways (Figure 3). Nevertheless, 
Figure 3. Inflammation pathways that involve IL-6.
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Figure 4. Effects of TNF-α production of free fatty acids in hepatocytes and adipocytes.
studies confirmed that IL-6 also controls processes involved in the resolution of inflammation, 
emphasizing its anti-inflammatory function [57].
4.2. Interleukin-6 in metabolic syndrome
Studies confirmed that IL-6 is correlated with all five of MetS components. The main explana-
tion relies on the fact that the dysfunctional adipose tissue induces macrophagic prolifera-
tion with increased IL-6 production [58]. Weiss et al. have found that IL-6 is associated with 
hypertriglyceridemia, fasting plasma glucose, and hypertension [59]. The same results are 
confirmed by Sarbijani et al. [17]. They also reported that increasing levels of IL-6 are corre-
lated with MetS severity [17, 59]. Also, Chedraui et al. found increased levels of IL-6 in women 
with abdominal obesity, lower levels of HDL-C, and hypertriglyceridemia [18]. Another 
study demonstrated that high IL-6 levels within hepatocytes in a state of chronic inflamma-
tion could be a determining cause of MetS development [60].
5. Tumoral necrosis factor-alpha
5.1. Tumoral necrosis factor-alpha in human metabolism
TNF-α is an inflammatory cytokine mainly produced by macrophage cells, but also by other 
type of inflammatory cells. Among its many roles, TNF-α is an acute inflammatory response 
protein, which increases C-reactive protein levels and also determines insulin resistance by 
interacting with insulin receptor [18]. TNF-α plays important roles in regulating lipid metabo-
lism (Figure 4), cholesterol metabolism, and adipokine synthesis [61].
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5.2. Tumoral necrosis factor-alpha and metabolic syndrome
TNF-α can be produced by inflammatory cells from the dysfunctional adipose tissue, similar 
to IL-6. TNF-α is involved in numerous MetS pathways and alterations, in insulin resis-
tance through similar mechanism of mTOR and protein C kinase activation and systemic 
inflammation [62]. As many studies have shown, TNF-α is being associated with all MetS 
components.
In the study by Moon et al. on obese adolescents, it was confirmed that TNF-α had higher 
levels in obese patients, even higher in male subjects, also, TNF-α positively correlated with 
BMI and waist circumference. Initially, TNF-α correlated positively with triglyceride levels 
and diastolic blood pressure, and inversely with HDL cholesterol, but after adjustment for 
BMI and waist circumference, only the association with triglyceride levels persisted [19].
In the meta-analysis of Sookoian et al. conducted on 16 homogeneous studies, it has been 
shown that obesity, systolic blood pressure, and serum insulin levels positively correlate with 
TNF-α -308A gene (genetic polymorphism that influences the plasmatic level of cytokine) 
variant and determine a 23% increased risk to develop MetS [20].
Obesity induces a systemic inflammatory status that determines dysfunctions of the mac-
rophages and adipocytes and inappropriate cytokine production [21]. As a result, higher 
levels of TNF-α determine insulin resistance through various mechanisms and promote dis-
ease progression in patients with MetS (Figure 5). Studies emphasize that insulin resistance 
caused by TNF-α is based on abnormal insulin signaling, overexpression of tissular and 
plasmatic levels of TNF-α in subjects with insulin resistance, and administration of TNF-α 
determines and TNF-α neutralization improves insulin resistance [22–25]. Therefore, TNF-α 
is involved in MetS pathogenesis and progression and could be used in determining patients 
with MetS.
Figure 5. TNF-α and insulin resistance.
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Figure 6. LDL oxidation products.
6. Oxidized low-density lipoproteins
6.1. Pathogenesis of oxidized LDL
In human organism, LDL particles undergo a series of oxidation processes, resulting in reac-
tive oxygen species (ROS) and oxidized LDL (Ox-LDL) particles. These products create nega-
tive electric charges that will cause macrophagic stimulation and inflammation.
During LDL oxidation process, a series of products are generated: fatty acid oxidation prod-
ucts, lipid-derived products, protein oxidation products (Figure 5) [63].
Lara-Guzman et al. have shown that THP-1 human macrophage exposure to Ox-LDL caused a 
series of changes, such as an increased intake of Ox-LDL, overexpression of its receptors, and 
ROS production. Likewise, in the same study, it has been demonstrated that Ox-LDL deter-
mines the synthesis of isoprostanes as oxidation markers and of prostaglandines and prosta-
glandine metabolites as inflammation markers. Therefore, this study emphasizes that Ox-LDL 
links oxidative stress with inflammation via macrophages, resulting in systemic and local con-
sequences [64]. Besides that, Schwarz et al. demonstrated that Ox-LDL increases Jun activation 
domain-binding protein-1 and stimulates inflammatory signaling in macrophages [65].
6.2. Oxidized LDL and endothelial dysfunction
Atherosclerosis represents one of the main alterations caused by MetS, and endothelial dys-
function is the earliest event within it. As mentioned earlier, Ox-LDL triggers inflammation 
and oxidation process that determines macrophagic activation and ROS production with 
cytotoxic effect on vascular endothelium [66].
Ox-LDL interacts with lectin-type oxidized LDL receptor 1 (LOX-1) from the surface of 
endothelial cells and determines their activation [67]. Withal, Ox-LDL causes endothelial 
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dysfunction by increasing endothelial adhesivity, by recruiting inflammatory cells into the 
endothelial wall, and by reducing nitric oxide production (Figure 6) [68, 69].
6.3. Oxidized LDL and metabolic syndrome
Various studies have shown that Ox-LDL levels are associated with MetS. Holvoet et al. dem-
onstrated that patients with MetS had higher Ox-LDL values. They also reported that hyper-
insulinemia and impaired glycemic control were associated with increased Ox-LDL levels, 
independent from lipid levels. The same research found that elevated Ox-LDL levels could 
predict the development of MetS in future [26].
Hurtado-Roca et al. in a study conducted on 3987 subjects demonstrated that Ox-LDL levels 
are positively correlated with MetS and its components even after adjustments for central 
obesity and insulin resistance. The strongest association was with triglyceride levels [27]. 
Another study conducted on overweighted/obese children showed that Ox-LDL positively 
correlated with BMI, percent body fat, waist circumference, percent trunk fat, abdominal vis-
ceral fat, abdominal subcutaneous fat (all p-values <0.0001), and with insulin resistance [28].
7. Pentraxin-3
7.1. The role of pentraxins in human organism
Pentraxins are a cluster of seric proteins with similar structures and calcium-dependent 
ligands that play important roles in body protection and in inflammatory mediation. The 
main mechanism is based on complement activation and interaction with Fc receptors [70].
PTX3 is being produced by immune cells as a response to bacterial substances, endotoxins, 
IL-1, and TNF-alpha. PTX3 is an acute phase protein with very low serum levels. PTX3 levels 
rise rapidly as a response to diverse inflammation stimuli. Therefore, PTX3 is considered to be 
a marker of local and general inflammatory and immune response [71–73].
7.2. Pentraxin-3 and metabolic syndrome
Recently, it has been shown that increased PTX3 levels are associated with MetS develop-
ment and progression. In a study conducted on adolescent subjects with obesity, Kardas et al. 
have shown that subjects with obesity and MetS had higher values of PTX3 than the subjects 
without MetS. They also observed that low HDL cholesterol and high triglyceride levels were 
associated with increased PTX3 levels [29]. Also, Zanetti et al. demonstrated that PTX3 was 
higher in patients with MetS and subclinical atherosclerosis and that PTX3 was indepen-
dently correlated with low HDL cholesterol levels [30]. Furthermore, a recent study found 
that PTX3 correlates with the severity of MetS, more precisely, after multivariate analysis 
PTX3 correlation persisted for glucose level (β = 0.23, p < 0.001), waist circumference (β = 0.37, 
p < 0.001), and HDL cholesterol (β = −0.31, p < 001) [31]. In conclusion, PTX3 could be a valu-
able biomarker in the prediction of MetS, but further studies should be conducted.
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8. Paraoxonase
8.1. Paraoxonase-1
PON-1 is an enzyme produced mostly by the liver that protects against lipid oxidation and 
exogenous toxics. PON-1 extends the lag phase of the oxidation process and reduces the alde-
hyde concentration, resulting in protective effects on LDL and HDL molecules [74]. Aharoni 
et al. in a murinic study demonstrated that PON-1 interacts with macrophages scavenger 
receptor class B type I, thus inhibiting IL-6 and TNF-α production and promoting PON-1 
anti-inflammatory effects [75].
The anti-inflammatory role of PON-1 is mainly validated by its anti-atherogenic effect [32]. 
Likewise, in the study of Ikhlef et al., it has been found that PON-1 could regulate cholesterol 
homeostasis by stimulating cholesterol efflux via HDL and by potentiating inverse cholesterol 
transport [33]. On the contrary, in subjects with diabetes, it is assumed that PON-1 becomes 
malfunctional by excessive glycation, thus it lowers its protective effects and potentiates the 
atherosclerotic lesion [34].
8.2. Paraoxonase 1 and metabolic syndrome
PON-1 has scientifically confirmed to be connected with MetS. A cross-sectional study con-
ducted on 354 Caucasian subjects with MetS has shown that PON-1 activity was significantly 
lower among patients who met all five MetS criteria (p < 0.05). The same study revealed that 
lower levels of HDL cholesterol and ApoA1 decrease the PON-1 activity [35]. A like, in a study 
conducted on 2404 subjects with MetS criteria, it has been demonstrated that PON-1 activity 
followed a downward trend with increasing MetS components and increasing lipid peroxides 
[76]. In conclusion, it is assumed that PON-1 through its antioxidant and anti-inflammatory 
effects could have important roles in lowering of the progression of MetS.
9. Interleukin-10
9.1. Interleukin-10 and metabolic syndrome
IL-10 is a potent anti-inflammatory cytokine that modulates the immune response in order 
to prevent excessive activation and auto-damage [36]. Based on its properties, IL-10 plays 
important roles in modulating insulin resistance and atherosclerotic development and, in a 
cross-sectional study conducted on children and young adolescents, it has been found that 
plasmatic IL-10 levels were lower in overweight/obese children, and they concluded that 
IL-10 could be a marker of metabolic risk [37]. On the contrary, Esposito et al. found that IL-10 
levels were lower in obese compared with normal weight women, but were lower in both 
groups that had MetS criteria [38]. Likewise, van Exel et al. found reduced plasmatic levels of 
IL-10 in patients with MetS and diabetes mellitus [39].
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9.2. Interleukin-10 and adiponectin
MetS is characterized by low levels of both adiponectin and IL-10, and recent studies have been 
evaluating if there is any link between the two molecules. In a study conducted on 117 men, it 
has been found that IL-10 levels significantly correlated with adiponectin levels especially in 
patients with MetS, but the correlation was stronger in MetS patients who presented abdomi-
nal obesity [77]. Also, Wolf et al. demonstrated that adiponectin modulates human monocytes 
and macrophages in producing anti-inflammatory cytokines such as IL-10 and IL-1RA [78].
10. Conclusions
The combined use of biomarkers of MetS could increase the rate of an early diagnosis and 
could prevent the complications of this disease. Associated usage of these biomarkers would 
increase their predictive value. However, to be able to create a diagnosis algorithm, their 
cutoff value for the presence of MetS and the causes that would yield false results should 
be determined. Last but not least, the usefulness of these biomarkers could be extended into 
guiding pharmacological and non-pharmacological therapeutic interventions. Also, treat-
ment efficiency could be monitored by determining these biomarkers dynamically.
Author details
Alexandru Zlibut1, Lucia Agoston-Coldea1*, Teodora Mocan2, Ioana Corina Bocsan3 and 
Lucian Mocan4
*Address all correspondence to: luciacoldea@yahoo.com
1 2nd Department of Internal Medicine, Iuliu Hatieganu University of Medicine and 
Pharmacy, Cluj-Napoca, Romania
2 Department of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, 
Cluj-Napoca, Romania
3 Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu Hatieganu 
University of Medicine and Pharmacy, Cluj-Napoca, Romania
4 3rd Department of General Surgery, Iuliu Hatieganu University of Medicine and 
Pharmacy, Cluj-Napoca, Romania
References
[1] Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—A new world-wide definition. 
A consensus statement from the international diabetes federation. Diabetic Medicine. 
2006;23:469-480
Biomarkers in Metabolic Syndrome
http://dx.doi.org/10.5772/intechopen.79427
99
[2] Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing 
the metabolic syndrome: A joint interim statement of the International Diabetes Federation 
Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; 
American Heart Association; World Heart Federation; International Atherosclerosis 
Society; and International Association for the Study of Obesity. Circulation. 2009;120: 
1640-1645. DOI: 10.1161/ CIRCULATIONAHA.109.192644
[3] Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, Koenig W. Associations between 
leptin and the leptin/adiponectin ratio and incident Type 2 diabetes in middle-aged men 
and women: Results from the MONICA/KORA Augsburg study 1984-2002. Diabetic 
Medicine. 2010;27:1004-1011. DOI: 10.1111/j.1464-5491.2010.03043.x
[4] García-Jiménez S, Bernal FG, Martínez MF, Monroy NA, Toledano JC, Meneses AA, 
et al. Serum leptin is associated with metabolic syndrome in obese Mexican subjects. 
Journal of Clinical Laboratory Analysis. 2015;29:5-9. DOI: 10.1002/jcla.21718
[5] Yoshinaga M, Sameshima K, Tanaka Y, Wada A, Hashiguchi J, Tahara H, et al. Adipokines 
and the prediction of the accumulation of cardiovascular risk factors or the presence of 
metabolic syndrome in elementary school children. Circulation Journal. 2008;72:1874-
1878. DOI: 10.1253/circj.CJ-08-0180
[6] Lee SW, Jo HH, Kim MR, You YO, Kim JH. Association between metabolic syndrome and 
serum leptin levels in postmenopausal women. Journal of Obstetrics and Gynaecology. 
2012;32:73-77. DOI: 10.3109/01443615.2011.618893
[7] Gannage-Yared MH, Khalife S, Semaan M, Fares F, Jambart S, Halaby G. Serum adi-
ponectin and leptin levels in relation to the metabolic syndrome, androgenic profile 
and somatotropic axis in healthy non-diabetic elderly men. European Journal of 
Endocrinology. 2006;155:167-176. DOI: 10.1530/eje.1.02175
[8] Yun JE, Kimm H, Jo J, Jee SH. Serum leptin is associated with metabolic syndrome in 
obese and nonobese Korean populations. Metabolism. 2010;59:424-429. DOI: 10.1016/j.
metabol.2009.08.012
[9] Santaniemi M, Kesaniemi YA, Ukkola O. Low plasma adiponectin concentration is an 
indicator of the metabolic syndrome. European Journal of Endocrinology. 2006;155:745-
750. DOI: 10.1530/eje.1.02287
[10] McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE. Plasma ghrelin con-
centrations are decreased in insulin-resistant obese adults relative to equally obese 
insulin-sensitive controls. The Journal of Clinical Endocrinology and Metabolism. 
2004;89:1630-1635. DOI: 10.1210/jc.2003-031572
[11] Chedraui P, Perez-Lopez FR, Escobar GS, Pallac G, Montt-Guevara M, Cecchi E, et al. 
Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insu-
lin resistance in postmenopausal women with and without the metabolic syndrome. 
Maturitas. 2014;79:86-90. DOI: 10.1016/j.maturitas.2014.06.008
Ultimate Guide to Insulin100
[12] Mora M, Adam V, Palomera E, Blesa S, Díaz G, Buquet X. Ghrelin gene variants influ-
ence on metabolic syndrome components in aged Spanish population. PLoS One. 
2015;10:e0136931. DOI: 10.1371/journal.pone.0136931
[13] Tabak O, Gelişgen R, Cicekçi H, Senateş E, Erdenen F, Müderrisoğlu C. Circulating lev-
els of adiponectin, orexin-A, ghrelin and the antioxidant paraoxonase-1 in metabolic 
syndrome. Minerva Medica. 2012;103:323-329
[14] Ahmed MB, Ismail MI1, Meki AR. Relation of osteoprotegerin, visfatin and ghrelin to 
metabolic syndrome in type 2 diabetic patients. International Journal of Health Sciences. 
2015;9:127-139
[15] Cho HY, Lee SY, Jeong DW, Cho AR, Jeon JS, KIM YJ, et al. Metabolic syndrome is asso-
ciated with lower plasma levels of desacyl ghrelin and total ghrelin in asymptomatic 
middle-aged Korean men. Journal of Obesity & Metabolic Syndrome. 2017;26:114-121. 
DOI: 10.7570/jomes.2017.26.2.114
[16] Langenberg C, Bergstrom J, Laughlin GA, Barrett-Connor E. Ghrelin, adiponectin, 
and leptin do not predict long-term changes in weight and body mass index in older 
adults: Longitudinal analysis of the Rancho Bernardo cohort. American Journal of 
Epidemiology. 2005;162:1189-1197. DOI: 10.1093/aje/kwi338
[17] Sarbijani HM, Khoshnia M, Marjani. The association between metabolic syndrome and 
serum levels of lipid peroxidation and interleukin-6 in Gorgan. Diabetes and Metabolic 
Syndrome: Clinical Research and Reviews. 2016;10:86-89. DOI: 10.1016/j.dsx.2015.09.024
[18] Chedraui P, Escobar GS, Pérez-López FR, Palla G, Montt-Guevara M, Cecchi E. Angiogenesis, 
inflammation and endothelial function in postmenopausal women screened for the 
metabolic syndrome. Maturitas. 2014;77:370-374. DOI: 10.1016/j.maturitas.2014.01.014
[19] Moon YS, Kim DH, Song DK. Serum tumor necrosis factor-alpha levels and components of 
the metabolic syndrome in obese adolescents. Metabolism. 2004;53:863-867. DOI: 10.1016/j.
metabol.2004.02.007
[20] Sookoian SC, Gonzalez C, Pirola CJ. Meta-analysis on the G-308A tumor necrosis fac-
tor α gene variant and phenotypes associated with the metabolic syndrome. Obesity 
Research. 2005;13:2122-2131. DOI: 10.1038/oby.2005.263
[21] Wang B, Trayhurn P. Acute and prolonged effects of TNF-alpha on the expression and 
secretion of inflammation-related adipokines by human adipocytes differentiated in 
culture. Pflügers Archiv. 2006;452:418-427. DOI: 10.1007/s00424-006-0055-8
[22] Borst SE. The role of TNF-alpha in insulin resistance. Endocrine. 2004;23:177-182. DOI: 
10.1385/ENDO:23:2-3:177
[23] Hossain M, Faruque MO, Kabir G, Hassan N, Sikdar D, Nahar Q, Ali L. Association 
of serum TNF-α and IL-6 with insulin secretion and insulin resistance in IFG and 
Biomarkers in Metabolic Syndrome
http://dx.doi.org/10.5772/intechopen.79427
101
IGT subjects in a Bangladeshi population. International Journal of Diabetes Mellitus. 
2010;2:165-168. DOI: 10.1016/j.ijdm.2010.08.004
[24] Nieto-Vazquez I, Fernández-Veledo S, Krämer DK, Vila-Bedmar R, Garcia-Guerra L, 
Lorenzo M. Insulin resistance associated to obesity: The link TNF-alpha. Archives of 
Physiology and Biochemistry. 2008;114:183-194. DOI: 10.1080/13813450802181047
[25] Swaroop JJ, Rajarajeswari D, Naidu JN. Association of TNF-α with insulin resistance in 
type 2 diabetes mellitus. The Indian Journal of Medical Research. 2012;135:127-130. DOI: 
10.4103/0971-5916.93435
[26] Holvoet P, De Keyzer D, Jacobs DR. Oxidized LDL and the metabolic syndrome. Future 
Lipidology. 2008;3:637-649. DOI: 10.2217/17460875.3.6.637
[27] Hurtado-Roca Y, Bueno H, Fernandez-Ortiz A, Ordovas JM, Ibanez B, Fuster V, et al. 
Oxidized LDL is associated with metabolic syndrome traits independently of central 
obesity and insulin resistance. Diabetes. 2017;66:474-482. DOI: 10.2337/db16-0933
[28] Kelly AS, Jacobs DR, Sinaiko AR, Moran A, Steffen LM, Steinberger J. Relation of cir-
culating oxidized LDL to obesity and insulin resistance in children. Pediatric Diabetes. 
2010;11:552-555. DOI: 10.1111/j.1399-5448.2009.00640.x
[29] Kardas F, Akın L, Kurtoglu S, Kendirci M, Kardas Z. Plasma Pentraxin 3 as a biomarker 
of metabolic syndrome. Indian Journal of Pediatrics. 2015;82:35-38. DOI: 10.1007/
s12098-014-1542-0
[30] Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M. Circulating pentraxin 3 levels 
are higher in metabolic syndrome with subclinical atherosclerosis: Evidence for associa-
tion with atherogenic lipid profile. Clinical and Experimental Medicine. 2009;9:243-248
[31] Karakas MF, Buyukkaya E, Kurt M, Motor S, Akcay AB, Karakas E, et al. Serum 
Pentraxin-3 levels are associated with the severity of metabolic syndrome. Medical 
Principles and Practice. 2013;22:274-279. DOI: 10.1159/000343904
[32] Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of 
Paraoxonase 1: Implication in arteriosclerosis diseases. North American Journal of 
Medical Sciences. 2012;4:523-532. DOI: 10.4103/1947-2714.103310
[33] Ikhlef S, Berrougui H, Kamtchueng Simo O, Zerif E, Khalil A. Human paraoxonase 1 
overexpression in mice stimulates HDL cholesterol efflux and reverse cholesterol trans-
port. PLoS One. 2017;12:e0173385. DOI: 10.1371/journal.pone.0173385
[34] Mackness B, Mackness M. Anti-inflammatory properties of paraoxonase-1 in atherosclero-
sis. Advances in Experimental Medicine and Biology. 2010;660:143-151. DOI: 10.1007/ 
978-1-60761-350-3_13
[35] Staňková B, Vávrová L, Rychlíková J, Žák A. Changes in Paraoxonase 1 activity and 
concentration of conjugated dienes in connection with number of metabolic syndrome 
components. Klinical Biochemical Metabolism. 2016;24:88-93
Ultimate Guide to Insulin102
[36] Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and 
autoimmune disease. Critical Reviews in Immunology. 2012;32:23-63
[37] Chang JS, Bai CH, Huang ZC, Owaga E, Chao KC, Chang CC, et al. Interleukin 10 
and clustering of metabolic syndrome components in pediatrics. European Journal of 
Clinical Investigation. 2014;44:384-394. DOI: 10.1111/eci.12247
[38] Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, et al. Association 
of low interleukin-10 levels with the metabolic syndrome in obese women. The Journal of 
Clinical Endocrinology and Metabolism. 2003;88:1055-1058. DOI: 10.1210/jc.2002-021437
[39] van Exel E, Gussekloo J, de Craen AJ, Frölich M, Bootsma-Van Der Wiel A, Westendorp 
RG. Low production capacity of interleukin-10 associates with the metabolic syndrome 
and type 2 diabetes: The Leiden 85-plus study. Diabetes. 2002;51:1088-1092. DOI: 10.2337/
diabetes.51.4.1088
[40] Mantzoros CS. The role of leptin in human obesity and disease: A review of current 
evidence. Annals of Internal Medicine. 1990;130:671-680. DOI: 10.7326/0003-4819-130-8- 
199904200-00014
[41] Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. Journal of Immunology. 
2005;174:3137-3142. DOI: 10.4049/jimmunol.174.6.3137
[42] Hegyi K, Fülöp K, Kovács K, Tóth S, Falus A. Leptin-induced signal transduction path-
ways. Cell Biology International. 2004;28:159-169. DOI: 10.1016/j.cellbi.2003.12.003
[43] Maroni P, Bendinelli P, Piccoletti R. Intracellular signal transduction pathways induced 
by leptin in C2C12 cells. Cell Biology International. 2005;29:542-550. DOI: 10.1016/j.
cellbi.2005.03.008
[44] Dong R, Ren J. What fans the fire: Insights into mechanisms of leptin in metabolic syn-
drome-associated heart diseases. Current Pharmaceutical Design. 2014;20:652-658. DOI: 
10.2174/138161282004140213160930
[45] Robinson K, Prins J, Venkatesh B. Clinical review: Adiponectin biology and its role in 
inflammation and critical illness. Critical Care. 2011;15:221. DOI: 10.1186/cc10021
[46] Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syn-
drome. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:29-33. DOI: 10.1161/01.
ATV.0000099786.99623.EF
[47] Fu Y. Adiponectin signaling and metabolic syndrome. Progress in Molecular Biology 
and Translational Science. 2014;121:293-319. DOI: 10.1016/B978-0-12-800101-1.00009-0
[48] Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, et al. Correlation 
of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic indi-
viduals. Diabetologia. 2009;52:2345-2349. DOI: 10.1007/s00125-009-1508-3
[49] López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega 
J, Gómez-Rodríguez A. The role of leptin/adiponectin ratio in metabolic syndrome and 
Biomarkers in Metabolic Syndrome
http://dx.doi.org/10.5772/intechopen.79427
103
diabetes. Hormone Molecular Biology and Clinical Investigation. 2014;18:37-45. DOI: 
10.1515/hmbci-2013-0053
[50] Kotani K, Sakane N. Leptin:adiponectin ratio and metabolic syndrome in the general 
Japanese population. The Korean Journal of Laboratory Medicine. 2011;31:162-166. DOI: 
10.3343/kjlm.2011.31.3.162
[51] Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-
hormone-releasing-acylated peptide from stomach. Nature. 1999;402:656-660. DOI: 
10.1038/45230
[52] Cowley MA, Smith RG, Diano S, Tschöp M, Pronchuk N, Grove KL. The distribu-
tion and mechanism of action of ghrelin in the CNS demonstrates a novel hypotha-
lamic circuit regulating energy homeostasis. Neuron. 2003;37:649-661. DOI: 10.1016/
S0896-6273(03)00063-1
[53] Pradhan G, Samson SL, Sun Y. Ghrelin: Much more than a hunger hormone. Current 
Opinion in Clinical Nutrition and Metabolic Care. 2014;16:619-624. DOI: 10.1097/
MCO.0b013e328365b9be
[54] Barazzoni R, Zanetti M, Ferreira C, Vinci P, Pirulli A, Mucci M. Relationships between 
desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. The 
Journal of Clinical Endocrinology and Metabolism. 2007;92:3935-3940. DOI: 10.1210/
jc.2006-2527
[55] Ukkola O. Ghrelin and metabolic disorders. Current Protein & Peptide Science. 2009;10:2-7. 
DOI: 10.2174/138920309787315220
[56] Qu D, Liu J, Lau CW, Huang Y. IL-6 in diabetes and cardiovascular complications. British 
Journal of Pharmacology. 2014;171:3595-3603. DOI: 10.1111/bph.12713
[57] Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nature 
Immunology. 2015;16:448-457. DOI: 10.1038/ni.3153
[58] Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR. Maladaptive immune and 
inflammatory pathways lead to cardiovascular insulin resistance. Metabolism. 2013;62: 
1543-1552
[59] Weiss TW, Arnesen H, Seljeflot I. Components of the interleukin-6 transsignalling sys-
tem are associated with the metabolic syndrome, endothelial dysfunction and arterial 
stiffness. Metabolism. 2013;62:1008-1013. DOI: 10.1016/j.metabol.2013.07.001
[60] Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. In: Begley TP, Means 
AR, O’Malley BW, Riddiford L, Tashjian AH, editors. Vitamins and Hormones. 80th 
Volume. Amsterdam: Elsevier; 2009. pp. 613-633. DOI: 10.1016/S0083-6729(08)00621-3
[61] Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha 
inhibits signaling from the insulin receptor. Proceedings of the National Academy of 
Sciences of the United States of America. 1994;91:4854-4858. DOI: 10.1073/pnas.91.11.4854
Ultimate Guide to Insulin104
[62] Chen X, Xun K, Chen L, Wang Y. TNF-alpha, a potent lipid metabolism regulator. Cell 
Biochemistry and Function. 2009;27:407-416. DOI: 10.1002/cbf.1596
[63] Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipo-
protein. Methods in Molecular Biology. 2010;610:403-417. DOI: 10.1007/978-1-60327-029-8_24
[64] Lara-Guzmán OJ, Gil-Izquierdo A, Medina S, Osorio E, Álvarez-Quintero R, Zuluaga N, 
et al. Oxidized LDL triggers changes in oxidative stress and inflammatory biomarkers 
in human macrophages. Redox Biology. 2018;15:1-11. DOI: 10.1016/j.redox.2017.11.017
[65] Schwarz A, Bonaterra GA, Schwarzbach H, Kinscherf R. Oxidized LDL-induced JAB1 
influences NF-κB independent inflammatory signaling in human macrophages dur-
ing foam cell formation. Journal of Biomedical Science. 2017;24(12). DOI: 10.1186/
s12929-017-0320-5
[66] Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Ariba Y, et al. An endo-
thelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73-77. DOI: 10.1038/ 
386073a0
[67] Frostegard J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified LDL 
increases the adhesive properties of endothelial cells. Atherosclerosis. 1991;90:119-126. 
DOI: 10.1016/0021-9150(91)90106-D
[68] Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density 
lipoproteins: A potential role in recruitment and retention of monocyte/macrophages 
during atherogenesis. Proceedings of the National Academy of Sciences of the United 
States of America. 1987;84:2995-2998
[69] Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein 
displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and 
impairs eNOS activation. The Journal of Biological Chemistry. 1999;274:32512-32519. 
DOI: 10.1074/jbc.274.45.32512
[70] Martinez de la Torre Y, Fabbri M, Jaillon S, Bastone A, Nebuloni M, Vecchi A, et al. 
Evolution of the pentraxin family: The new entry PTX4. Journal of Immunology. 
2010;184:5055-5064. DOI: 10.4049/jimmunol.0901672
[71] Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between 
innate immunity, inflammation, matrix deposition, and female fertility. Annual Review 
of Immunology. 2005;23:337-366. DOI: 10.1146/annurev.immunol.23.021704.115756
[72] Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, Mantovani A. Circulating 
levels of the long pentraxin PTX3 correlate with severity of infection in critically ill 
patients. Critical Care Medicine. 2001;29:1404-1407
[73] Ohbayashi H, Miyazawa C, Miyamoto K, Sagara M, Yamashita T, Onda R. Pitavastatin 
improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with 
hypercholesterolemia. Journal of Atherosclerosis and Thrombosis. 2009;16:490-500
Biomarkers in Metabolic Syndrome
http://dx.doi.org/10.5772/intechopen.79427
105
[74] Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein 
against oxidative modification by high-density lipoprotein associated paraoxonase. 
Atherosclerosis. 1993;104:129-135. DOI: 10.1016/0021-9150(93)90183-U
[75] Aharoni S, Aviram M, Fuhrman B. Paraoxonase 1 (PON1) reduces macrophage inflam-
matory responses. Atherosclerosis. 2013;228:353-361. DOI: 10.1016/j.atherosclerosis.2013. 
03.005
[76] Senti M, Tomas M, Fito M, Weinbrenner T, Covas MI, Sala J, et al. Antioxidant Paraoxonase 
1 activity in the metabolic syndrome. The Journal of Clinical Endocrinology and Metabo-
lism. 2003;88:5422-5426. DOI: 10.1210/jc.2003-030648
[77] Nishida M, Moriyama T, Sugita Y, Yamauchi-Takihara K. Interleukin-10 associates with 
adiponectin predominantly in subjects with metabolic syndrome. Circulation Journal. 
2007;71:1234-1238. DOI: 10.1253/circj.71.1234
[78] Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflam-
matory cytokines IL-10 and IL-1RA in human leukocytes. Biochemical and Biophysical 
Research Communications. 2004;323:630-635. DOI: 10.1016/j.bbrc.2004.08.145
Ultimate Guide to Insulin106
